Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CAIV-T, Liquid · 10 trials · 1 indication
The geometric mean titers for each strain between Day 0 and 28 were examined.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | CAIV-T |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Cold-adapted influenza vaccine (CAIVT) | EXPERIMENTAL | A single intranasal dose of 10\^7 fluorescent focus units. |
| Trivalent inactivated vaccine (TIV) | ACTIVE_COMPARATOR | A single dose of commercially available Flushield was administered intramuscularly. |
| Placebo | PLACEBO_COMPARATOR | The 0.2 mL administered intranasally. |
| Name | Type | Description |
|---|---|---|
| CAIV-T | BIOLOGICAL | - |
| Placebo | OTHER | A single dose of placebo volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril). |
| TIV | OTHER | A total vol. of 0.25 will be administered intramuscularly for each of two doeses. |
| CAIV-T, Liquid | BIOLOGICAL | - |
Inclusion Criteria: * who are aged at least 6 months and less than 36 months of age at the time of first vaccination * who have received a full primary vaccination schedule consisting of three doses of OPV in the first year of life * who are in good health as determined by medical history, physical...
CAIV-T is an investigational trivalent cold-adapted influenza vaccine being studied for the prevention of influenza. It has been evaluated in clinical trials involving healthy children, including those as young as 6 months, as well as healthy adults and individuals with asthma.
CAIV-T is being developed by AstraZeneca PLC, which trades under the ticker symbol AZN. The company has sponsored multiple clinical trials of this vaccine candidate across different age groups and countries.
CAIV-T is in Phase 3 clinical development. It has completed 10 clinical trials with a total enrollment of 9,986 participants. The trials were randomized, double-blind, and active-controlled, and none are currently ongoing.
CAIV-T has been studied in several completed trials, including NCT00111579, which compared immune responses of CAIV-T with trivalent inactivated vaccine (TIV) in 52 participants, and NCT00192166, which assessed safety and immunogenicity when given with MMR vaccine in 1,200 healthy children aged 11 to 24 months.
CAIV-T is a live attenuated influenza vaccine, not an inactivated flu shot. It is administered intranasally and is designed to induce immune responses similar to natural infection. It has been compared directly with trivalent inactivated vaccine (TIV) in clinical trials.
CAIV-T is a cold-adapted live attenuated influenza vaccine. It contains weakened influenza viruses that replicate in the cooler temperatures of the nasal passages, stimulating an immune response without causing full-blown illness. This mechanism is intended to provide protection against influenza.